Geospiza and NuGEN Integrate Cloud Software and Sample Preparation to Accelerate Results using Next-Gen Sequencing
SEATTLE – Geospiza, Inc., the market leading developer of genetic analysis software, and NuGEN Technologies, Inc., the leader in sample preparation solutions for clinical samples, today announced a co-marketing agreement to develop a seamless next-generation sequencing workflow to accelerate discoveries for large disease research studies.
“There is a need to speed research and discovery using methodologies such as Next Generation Sequencing, especially for disease studies involving a large number of samples,” said Brandon Young, Genomic Core Manager at The Scripps Research Institute. “We’re looking forward to testing the integrated workflow.”
“Geospiza’s lab and analysis software tools are focused on making research easier, faster and more cost effective,” said Rob Arnold, Geospiza’s President. “Combining our GeneSifter® preconfigured lab and analysis cloud software with NuGEN’s OvationÒand Encore™ reagents enables researchers to follow and document a step-by-step best practice for sample preparation combined with fully integrated data analysis and other sample information in one system.”
“Our innovative sample preparation capabilities complement nicely with Geospiza’s platform,” said Elizabeth Hutt, CEO of NuGEN Technologies. “Together NuGEN and Geospiza are developing a scalable integrated workflow that accelerates throughput and removes sample preparation and analysis bottlenecks in next-gen sequencing.”
About Geospiza
Designed by biologists for biologists, Geospiza is the market leading developer of GeneSifter® software, providing integrated solutions for Next Generation Sequencing analysis and LIMS. For over 10 years, Geospiza has set the industry standard for high value, low cost, “out of the box” solutions serving the life sciences market. You can find more information on Geospiza and its products at www.geospiza.com.
About NuGEN
NuGEN is a provider of innovative genomics sample preparation solutions enabling scientists to access true biology in all samples independent of type, quality and size for analysis on leading analytical platforms. Committed to advancing the life sciences, NuGEN ensures robust and reproducible results for researchers seeking to predict disease risk and drug response, potentially shortening the path to treatment. For more information please visit www.nugeninc.com.
